Inspire Medical Systems (NYSE:INSP) Price Target Raised to $70.00

Inspire Medical Systems (NYSE:INSP) had its price objective increased by Piper Sandler from $60.00 to $70.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other research analysts have also commented on INSP. KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Royal Bank Of Canada upped their price target on Inspire Medical Systems from $60.00 to $75.00 and gave the company a “sector perform” rating in a research report on Thursday, October 1st. Wells Fargo & Company raised their price objective on Inspire Medical Systems from $56.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Finally, Stifel Nicolaus lifted their price objective on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $71.24.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $66.45 on Tuesday. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The company’s 50-day simple moving average is $68.89 and its 200-day simple moving average is $58.38. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 4.87 and a beta of 0.67.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $206.69 million during the quarter, compared to the consensus estimate of $204.31 million. Inspire Medical Systems had a return on equity of 7.32% and a net margin of 11.43%. The company’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period last year, the firm earned $0.38 earnings per share. As a group, research analysts forecast that Inspire Medical Systems will post 1.29 EPS for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of large investors have recently bought and sold shares of INSP. Pinnacle Wealth Planning Services Inc. lifted its stake in Inspire Medical Systems by 19.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock valued at $81,000 after buying an additional 194 shares during the last quarter. Apollon Wealth Management LLC grew its position in shares of Inspire Medical Systems by 5.6% during the first quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock worth $206,000 after acquiring an additional 212 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Inspire Medical Systems by 25.0% during the third quarter. GAMMA Investing LLC now owns 1,526 shares of the company’s stock worth $106,000 after acquiring an additional 305 shares during the last quarter. Yousif Capital Management LLC grew its position in shares of Inspire Medical Systems by 5.7% during the third quarter. Yousif Capital Management LLC now owns 7,552 shares of the company’s stock worth $524,000 after acquiring an additional 405 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Inspire Medical Systems by 68.5% during the third quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock worth $83,000 after acquiring an additional 488 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Piper Sandler and Robert W. Baird were reported as expecting the stock to appreciate, offering some support amid weaker sentiment. Piper Sandler forecast Baird forecast
• Positive Sentiment: A bullish analysis argued Inspire’s competitive advantage held up under a severe stress test, suggesting the company may retain durable long-term strengths. Bullish competitive-position analysis
• Neutral Sentiment: Q3 results were mixed: revenue of $206.7 million modestly exceeded estimates, while falling 7.9% year over year; reported EPS of $0.14 beat the $0.09 consensus but was below $0.38 a year earlier. This points to continued growth and profitability concerns despite the estimate beats. Q3 earnings call summary
• Negative Sentiment: Inspire narrowed its full-year 2026 earnings guidance, a signal investors may interpret as reduced visibility or a weaker outlook. 2026 guidance update
• Negative Sentiment: Barclays maintained its Sell rating, and coverage linked an analyst downgrade to a sharp decline in the shares. This adds pressure alongside questions about cash flow and whether the stock has fallen enough. Barclays rating Cash-flow valuation discussion

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.